Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study

Ozlem Yilmaz1,2,3, Anne Daly1, Alex Pinto1

  • 1Birmingham Women's and Children's Hospital, Birmingham B4 6NH, UK.

Nutrients
|September 28, 2021
PubMed

Insights

Hereditary tyrosinaemia type I (HTI) patients showed improved growth over time, with height, weight, and BMI z-scores increasing with age. Protein intake positively impacted height growth in this cohort.

Area of Science:

  • Pediatrics
  • Metabolic Disorders
  • Genetics

Background:

  • Hereditary tyrosinaemia type I (HTI) is a rare genetic disorder affecting amino acid metabolism.
  • Long-term growth patterns in HTI patients require further investigation.

Purpose of the Study:

  • To assess long-term growth outcomes in patients with hereditary tyrosinaemia type I.
  • To identify factors influencing growth in HTI patients.

Main Methods:

  • Retrospective review of 17 HTI patients.
  • Analysis of height, weight, and BMI z-scores over time.
  • Correlation of growth with protein intake.

Main Results:

  • HTI patients exhibited improved height, weight, and BMI z-scores with age, approaching normal population standards.
  • Overweight and obesity prevalence increased from <5 years to 7-16 years.
  • Higher prescribed total protein intake was linked to better height growth (p < 0.01).

Conclusions:

  • Growth impairment in early life can improve with age in HTI patients.
  • Protein intake is a significant factor in height development.
  • Further research is needed to fully understand growth determinants in HTI.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
335
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
35
Pedigree Analysis01:35

Pedigree Analysis

Overview
86.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Heritability01:06

Heritability

Heritability is a statistical concept that measures the degree to which genetic differences among individuals contribute to trait variations within a population. It is a fundamental idea in genetics, often prone to misinterpretation. Heritability is expressed as a percentage, reflecting the proportion of variation in a specific trait across a population that can be linked to genetic differences. However, it's important to understand that heritability does not determine how "genetic"...
369